Cargando…

Assessment of Quantitative and Allelic MGMT Methylation Patterns as a Prognostic Marker in Glioblastoma

Methylation of the O(6)-methylguanine-DNA methyltransferase (MGMT) gene is a predictive and prognostic marker in newly diagnosed glioblastoma patients treated with temozolomide but how MGMT methylation should be assessed to ensure optimal detection accuracy is debated. We developed a novel quantitat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kristensen, Lasse S., Michaelsen, Signe R., Dyrbye, Henrik, Aslan, Derya, Grunnet, Kirsten, Christensen, Ib J., Poulsen, Hans S., Grønbæk, Kirsten, Broholm, Helle
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2016
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4777218/ https://www.ncbi.nlm.nih.gov/pubmed/26883115 http://dx.doi.org/10.1093/jnen/nlv024

Ejemplares similares

DNA Methylation Levels of the ELMO Gene Promoter CpG Islands in Human Glioblastomas
por: Michaelsen, Signe Regner, et al.
Publicado: (2018)

Clinical variables serve as prognostic factors in a model for survival from glioblastoma multiforme: an observational study of a cohort of consecutive non-selected patients from a single institution
por: Michaelsen, Signe Regner, et al.
Publicado: (2013)

Clinical Characteristics of Gliosarcoma and Outcomes From Standardized Treatment Relative to Conventional Glioblastoma
por: Frandsen, Simone, et al.
Publicado: (2019)

Angiotensinogen promoter methylation predicts bevacizumab treatment response of patients with recurrent glioblastoma
por: Urup, Thomas, et al.
Publicado: (2020)

A Prognostic Model for Glioblastoma Patients Treated With Standard Therapy Based on a Prospective Cohort of Consecutive Non-Selected Patients From a Single Institution
por: Abedi, Armita Armina, et al.
Publicado: (2021)

Investigation of MGMT and DAPK1 methylation patterns in diffuse large B-cell lymphoma using allelic MSP-pyrosequencing
por: Kristensen, Lasse Sommer, et al.
Publicado: (2013)

Extracranial metastases in glioblastoma—Two case stories
por: Schou Nørøxe, Dorte, et al.
Publicado: (2018)

(18)F-FET MicroPET and MicroMRI for Anti-VEGF and Anti-PlGF Response Assessment in an Orthotopic Murine Model of Human Glioblastoma
por: Nedergaard, Mette Kjoelhede, et al.
Publicado: (2015)

The prognostic value of FET PET at radiotherapy planning in newly diagnosed glioblastoma
por: Poulsen, Sidsel Højklint, et al.
Publicado: (2016)

Association between MGMT Enhancer Methylation and MGMT Promoter Methylation, MGMT Protein Expression, and Overall Survival in Glioblastoma
por: Zappe, Katja, et al.
Publicado: (2023)

Hypermethylation of DAPK1 is an independent prognostic factor predicting survival in diffuse large B-cell lymphoma
por: Kristensen, Lasse Sommer, et al.
Publicado: (2014)

Quantitative Analysis of the MGMT Methylation Status of Glioblastomas in Light of the 2021 WHO Classification
por: Häni, Levin, et al.
Publicado: (2022)

Quantitative analysis of MGMT promoter methylation in glioblastoma suggests nonlinear prognostic effect
por: Gibson, David, et al.
Publicado: (2023)

Long Non-Coding RNAs Guide the Fine-Tuning of Gene Regulation in B-Cell Development and Malignancy
por: Dahl, Mette, et al.
Publicado: (2018)

MGMT promoter methylation in Peruvian patients with glioblastoma
por: Belmar-Lopez, Carolina, et al.
Publicado: (2018)

Prognostic prediction of glioblastoma by quantitative assessment of the methylation status of the entire MGMT promoter region
por: Kanemoto, Manabu, et al.
Publicado: (2014)

Prognostic Role of Methylation Status of the MGMT Promoter Determined Quantitatively by Pyrosequencing in Glioblastoma Patients
por: Kim, Dae Cheol, et al.
Publicado: (2016)

Clinical validation of a novel quantitative assay for the detection of MGMT methylation in glioblastoma patients
por: Rosas-Alonso, Rocio, et al.
Publicado: (2021)

Transcriptional changes induced by bevacizumab combination therapy in responding and non-responding recurrent glioblastoma patients
por: Urup, Thomas, et al.
Publicado: (2017)

MGMT Methylation Status: The Advent of Stratified Therapy in Glioblastoma?
por: Hau, Peter, et al.
Publicado: (2007)

An evaluation of MGMT promoter methylation within the methylation subclasses of glioblastoma
por: Alnahhas, Iyad, et al.
Publicado: (2020)

A ”Clickable” Probe for Active MGMT in Glioblastoma Demonstrates Two Discrete Populations of MGMT
por: Raghavan, Sudhir, et al.
Publicado: (2020)

NGMA-6. Quantitative MGMT Promoter Methylation Index Indicates Non-Linear, Prognostic Effect in Glioblastoma
por: Gibson, David, et al.
Publicado: (2021)

Hypermethylation of the VTRNA1-3 Promoter is Associated with Poor Outcome in Lower Risk Myelodysplastic Syndrome Patients
por: Søgaard Helbo, Alexandra, et al.
Publicado: (2015)

TP53 hotspot mutations are predictive of survival in primary central nervous system lymphoma patients treated with combination chemotherapy
por: Munch-Petersen, Helga D., et al.
Publicado: (2016)

The MGMT promoter single-nucleotide polymorphism rs1625649 had prognostic impact on patients with MGMT methylated glioblastoma
por: Hsu, Chih-Yi, et al.
Publicado: (2017)

Personalized treatment strategies in glioblastoma: MGMT promoter methylation status
por: Thon, Niklas, et al.
Publicado: (2013)

Procarbazine and CCNU Chemotherapy for Recurrent Glioblastoma with MGMT Promoter Methylation
por: Kim, Se-Hyuk, et al.
Publicado: (2018)

Radiomics and MGMT promoter methylation for prognostication of newly diagnosed glioblastoma
por: Sasaki, Takahiro, et al.
Publicado: (2019)

MRI texture features as biomarkers to predict MGMT methylation status in glioblastomas
por: Korfiatis, Panagiotis, et al.
Publicado: (2016)

Appraisal of re-irradiation for the recurrent glioblastoma in the era of MGMT promotor methylation
por: Kim, Il Han
Publicado: (2019)

Tim-3 Expression and MGMT Methylation Status Association With Survival in Glioblastoma
por: Zhang, Ji, et al.
Publicado: (2020)

Identifying the optimal cutoff point for MGMT promoter methylation status in glioblastoma
por: Nguyen, Ngan, et al.
Publicado: (2021)

Prognostic Impact of the Combination of MGMT Methylation and TERT Promoter Mutation in Glioblastoma
por: Tunthanathip, Thara, et al.
Publicado: (2021)

Peritumoral ADC Values Correlate with the MGMT Methylation Status in Patients with Glioblastoma
por: Ladenhauf, Valentin Karl, et al.
Publicado: (2023)

VEGF-C sustains VEGFR2 activation under bevacizumab therapy and promotes glioblastoma maintenance
por: Michaelsen, Signe R, et al.
Publicado: (2018)

Volumetric and MGMT parameters in glioblastoma patients: Survival analysis
por: Iliadis, Georgios, et al.
Publicado: (2012)

Advances in the management of glioblastoma: the role of temozolomide and MGMT testing
por: Thomas, Reena P, et al.
Publicado: (2012)

Veliparib in combination with radiotherapy for the treatment of MGMT unmethylated glioblastoma
por: Jue, Toni Rose, et al.
Publicado: (2017)

Bortezomib administered prior to temozolomide depletes MGMT, chemosensitizes glioblastoma with unmethylated MGMT promoter and prolongs animal survival
por: Rahman, Mohummad Aminur, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_15s13nse7mvv688qs4ldhkuaj0